Dermira, Inc. (DERM) News
Filter DERM News Items
DERM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest DERM News From Around the Web
Below are the latest news stories about JOURNEY MEDICAL CORP that investors may wish to consider to help them evaluate DERM as an investment opportunity.
Despite Journey Medical's Pullback, Insiders Still Gained US$118kJourney Medical Corporation ( NASDAQ:DERM ) insiders who acquired shares over the previous 12 months, can probably... |
Journey Medical Corporation (DERM) Reports Q3 Loss, Tops Revenue EstimatesJourney Medical (DERM) delivered earnings and revenue surprises of 29.41% and 1.87%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate HighlightsU.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025 Total revenues for the third quarter ended September 30, 2024 were $14.6 million SCOTTSDALE, Ariz., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on the |
FDA approves Journey Medical’s rosacea treatment EmrosiJourney Medical's new rosacea treatment will rival industry giant Galderma's Oracea in the treatment of rosacea. |
Journey Medical (DERM) Soars 7.3%: Is Further Upside Left in the Stock?Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of RosaceaJourney Medical to host investor conference call on Monday, November 4, 2024, at 8:30 a.m. E.T.SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the FDA has approved Emrosi™ (Minocycline |
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology ConferencePoster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy Subjects With its modified-release formulation, DFD-29 (40 mg) provides higher dermal concentration than doxycycline from Day 1 onward at a similar dose, expected to translate into a clinically meaningful impact for treating patients with rosacea New Drug Application for DFD-29 under review by FDA with PDU |
SWK Holdings Provides Portfolio UpdateCompany Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 /SWK Holdings Corporation (Nasdaq:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized ... |
Journey Medical Corporation to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceSCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical’s management team will attend one-on-one meetings at the 3rd Annual ROTH Healthcare O |
Can Journey Medical Corporation (NASDAQ:DERM) Improve Its Returns?While some investors are already well versed in financial metrics (hat tip), this article is for those who would like... |